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A secondary analysis of REVASCAT trial
ABSTRACT
Objective: To investigate the effect of endovascular treatment on cognitive function as a prespe-
cified secondary analysis of the REVASCAT (Endovascular Revascularization With Solitaire
Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours) trial.
Methods: REVASCAT randomized 206 patients with anterior circulation proximal arterial occlu-
sion stroke to Solitaire thrombectomy or best medical treatment alone. Patients with established
dementia were excluded from enrollment. Cognitive function was assessed in person with Trail
Making Test (TMT) Parts A and B at 3 months and 1 year after randomization by an investigator
masked to treatment allocation. Test completion within 5 minutes, time of completion (seconds),
and number of errors were recorded.
Results: From November 2012 to December 2014, 206 patients were enrolled in REVASCAT.
TMT was assessed in 82 of 84 patients undergoing thrombectomy and 86 of 87 control patients
alive at 3 months and in 71 of 79 patients undergoing thrombectomy and 72 of 78 control pa-
tients alive at 1 year. Rates of timely TMT-A completion were similar in both treatment arms,
although patients undergoing thrombectomy required less time for TMT-A completion and had
higher rates of error-free TMT-A performance. Thrombectomy was also associated with a higher
probability of timely TMT-B completion (adjusted odds ratio 3.17, 95% confidence interval 1.51–
6.66 at 3 months; and adjusted ratio 3.66, 95% confidence interval 1.60–8.35 at 1 year) and
shorter time for TMT-B completion. Differences in TMT completion times between treatment
arms were significant in patients with good functional outcome but not in those who were func-
tionally dependent (modified Rankin Scale score .2). Poorer cognitive outcomes were signifi-
cantly associated with larger infarct volume, higher modified Rankin Scale scores, and worse
quality of life.
Conclusions: Thrombectomy improves TMT performance after stroke, especially among patients
who reach good functional recovery.
ClinicalTrials.gov identifier: NCT01692379.
Classification of evidence: This study provides Class I evidence that for patients with stroke from
acute anterior circulation proximal arterial occlusion, thrombectomy improves performance on the
TMT at 3 months. Neurology® 2017;88:245–251
GLOSSARY
EQ-5D 5 EuroQoL Group 5-Dimension Self-Report Questionnaire; mRS 5 modified Rankin Scale; REVASCAT 5 Endovas-
cular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours;
TMT 5 Trail Making Test.
Cognitive impairment is a common consequence of stroke,1–3 even in survivors with successful
functional recovery,4 and it is closely related to disability and dependency.2 Cognitive impair-
ment and dementia after stroke may involve multiple domains, attention and executive func-
tioning being particularly affected.1,3 Altered executive functioning early after stroke has been
reported as a predictor of long-term cognitive impairment.5
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Because cognitive outcome has traditionally
not been considered an outcome measure in
randomized trials investigating the benefit of
intravenous tissue plasminogen activator in
acute stroke, little knowledge exists with regard
to any potential benefit that intravenous tissue
plasminogen activator may have on cognition.
In a recent post hoc analysis based on pooled
data from the VISTA (Virtual International
Stroke Trials Archive) trials, the Cog-4 scale
(based on 4 items of NIH Stroke Scale) was
used as an indicator of cognitive function at 3
months after stroke. It was noted that the distri-
bution of Cog-4 scores was better in patients
who received intravenous recombinant tissue
plasminogen activator compared to those who
were not thrombolysed, although this scale
did not provide additional information beyond
the modified Rankin Scale (mRS) assessment.6
Endovascular treatment has recently demon-
strated benefit in physical disability and func-
tional outcome after acute stroke,7 but the
effect on cognitive outcomes has not been es-
tablished yet. REVASCAT (Endovascular
Revascularization With Solitaire Device Versus
Best Medical Therapy in Anterior Circulation
Stroke Within 8 Hours) randomized acute
stroke patients either to medical therapy plus
endovascular treatment thrombectomy or to
medical treatment alone. Analysis of the pri-
mary outcome consisting of ordinal mRS score
analysis at the third month revealed that throm-
bectomy was beneficial.8
A prespecified secondary outcome of
REVASCAT9 was to evaluate the effect of en-
dovascular treatment on cognitive functioning
at 3 months and 1 year after stroke as measured
by the Trail Making Test (TMT). We also
aimed to study the relationship among cognitive
outcomes and other stroke-relevant outcomes
(infarct volume, mRS score, and health-related
quality of life). To assess whether the influence
of endovascular treatment on TMT perfor-
mance was relevant beyond physical disability,
as a post hoc analysis, cognitive outcome was
evaluated separately in patients with good/poor
functional outcome (mRS score #2/.2).
METHODS Primary research question. Does thrombec-
tomy improve TMT performance at 3 months after acute ische-
mic stroke due to an anterior large vessel occlusion?
Classification of evidence. This randomized interventional
study provides Class I evidence that for patients with stroke from
acute anterior circulation proximal arterial occlusion, thrombec-
tomy improves performance on the TMT at 3 months compared
to best medical treatment alone. From November 2012 to
December 2014, REVASCAT enrolled 206 patients with stroke
of the anterior circulation within 8 hours from onset who were ran-
domized to receive thrombectomy (with a Solitaire device, Med-
tronic, Minneapolis, MN) or best medical treatment (both
including intravenous recombinant tissue plasminogen activator).
The trial was conducted in 4 comprehensive stroke centers in
Catalonia, Spain. Patients with established dementia were excluded
from enrollment. Detailed protocol and main results have previ-
ously been published.8,9 The trial was registered at Clinicaltrials.
gov (NCT01692379) and funded by an unrestricted grant from
the manufacturer of the device (Covidien, now Medtronic). The
primary outcome of REVASCAT was distribution of functional
outcome expressed as mRS score at 90 days. A prespecified
secondary objective was to test thrombectomy effects on
cognitive function at 3 months and 1 year after randomization.9
Cognitive function was assessed in person by an investigator
masked to treatment arm using TMT Parts A and B. TMT meas-
ures attention, processing speed, working memory, visuospatial
ability, and set shifting.10 TMT-A requires the patient to draw
lines sequentially connecting 25 encircled numbers distributed on
a sheet of paper. In TMT-B, the patient must alternate between
numbers and letters (e.g., 1-A-2-B-3-C.L-13). Before each test
trial, a practice trial of 6 items was administered to ensure task
understanding. Tests must be completed in a maximum of 5 mi-
nutes. During performance, each error was immediately corrected
by the examiner, and the patient was asked to continue the task.
For TMT-A and TMT-B, cognitive outcome was evaluated by
Figure 1 CONSORT flow diagram of patients included in REVASCAT trial
The diagram shows patient allocation, deaths, and individuals missing data for cognitive
evaluation in each treatment arm and at both times of follow-up (2 and 12 months after
randomization). CONSORT 5 Consolidated Standards of Reporting Trials; REVASCAT 5
Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in
Anterior Circulation Stroke Within 8 Hours. TMT 5 Trail Making Test.
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percentage of patients who completed the tests in the requested
time (5 minutes), time of completion of each test (in seconds),
and number of errors made (none vs one or more errors).
Infarct volumes (milliliters) at 24 hours on CT or MRI were
adjudicated by investigators at an independent imaging core lab-
oratory who were blinded to clinical data.8 Functional ability and
health-related quality of life were evaluated at 3 months and 1
year after enrollment by masked certified assessors using mRS and
EuroQoL Group 5-Dimension Self-Report Questionnaire
(EQ-5D) 3L, respectively. EQ-5D was analyzed with a utility
index adapted to the Spanish population (range 20.3 to 1) and
visual analog scale (range 0–100), with higher values correspond-
ing to better quality of life. Language impairment and right upper
limb paresis were evaluated with the specific NIH Stroke Scale
items at 3 months after stroke. This specific information was not
available at 1 year.
Standard protocol approvals, registrations, and patient
consents. The REVASCAT trial received approval from the
ethics committees on human experimentation at the 4 recruiting
centers. Written informed consent was obtained from all patients
(or relatives) participating in the study. The REVASCAT trial was
registered at Clinicaltrials.gov (NCT01692379).
Statistical analysis. Main analyses were performed in the com-
plete case population. The primary objective was to evaluate the
effect of treatment arm on executive cognitive outcome at 3
months and 1 year after randomization. Differences in TMT
completion on requested time (yes vs no) and presence of errors
(0 vs $1) between treatment arms were assessed with logistic
regression models, with the effect expressed as odds ratio and
95% confident interval. Difference in times of completion of
TMT (seconds) between treatment arms was assessed with mul-
tivariate linear regression models, with the effect expressed as the
mean difference (b coefficient and 95% confidence interval
for b). To avoid missing data, maximum time of completion
(300 seconds) was considered in those patients who could not
complete the tests in the requested time. Multivariable analyses
were adjusted by treatment arm, age, baseline stroke severity
(NIHSS Stroke Scale), and side of stroke. Association of TMT
performance (completion times) with other outcome measures
(infarct volume, mRS, EQ-5D) was assessed with Spearman
correlation coefficients.
To assess whether the influence of endovascular treatment on
TMT performance was relevant beyond physical disability, differ-
ences in time of completion of TMT between treatment arms
were evaluated separately in patients with mRS scores #2 and
those with mRS scores .2. In this stratified analysis, differences
were assessed with linear regression analysis.
RESULTS Executive cognitive function was assessed
in 82 of 84 patients undergoing thrombectomy and
86 of 87 control patients alive at 3 months and in
71 of 79 patients undergoing thrombectomy and
72 of 78 control patients alive at 1 year (see flow dia-
gram in figure 1). The percentage of patients who
Table 1 Cognitive outcomes in each treatment arm
EVT 1 BMT BMT alone Effect measure Unadjusted value (95% CI) Adjusted value (95% CI)a
TMT-A at 3 mo, n 82 86
Completion in due time, n (%) 60 (73.2) 58 (67.4) Odds ratio 1.32 (0.68 to 2.56) 1.48 (0.71 to 3.11)
Without errors, n (%) 47 (78.3) 34 (58.6) Odds ratio 2.55 (1.14 to 5.71) 2.45 (1.05 to 5.70)
Time of completion (raw), s 96.5 6 65.0 112.7 6 63.7 Mean difference 16.2 (27.3 to 39.7) 15.6 (26.3 to 37.6)
Time of completion (imputed), s 151.1 6 106.3 173.7 6 102.5 Mean difference 22.6 (29.2 to 54.4) 21.0 (26.1 to 48.1)
TMT-A at 1 y, n 71 72
Completion in due time, n (%) 54 (76.0) 48 (66.7) Odds ratio 1.59 (0.76 to 3.30) 2.00 (0.87 to 4.61)
Without errors, n (%) 44 (81.5) 30 (62.5) Odds ratio 2.64 (1.07 to 6.50) 3.50 (1.25 to 9.77)
Time of completion (raw), s 84.2 6 54.5 109.7 6 66.3 Mean difference 23.3 (0.4 to 46$1) 23.4 (1.1 to 45.8)
Time of completion (imputed), s 135.9 6 104.1 173.1 6 105.2 Mean difference 37.2 (2.6 to 71.8) 35.3 (4.5 to 66.2)
TMT-B at 3 mo, n 82 86
Completion in due time, n (%) 38 (46.3) 22 (25.6) Odds ratio 2.51 (1.31 to 4.81) 3.17 (1.51 to 6.66)
Without errors, n (%) 15 (39.5) 8 (36.4) Odds ratio 1.14 (0.39 to 3.38) 1.05 (0.33 to 3.38)
Time of completion (raw), s 155.6 6 68.7 173.9 6 71.7 Mean difference 18.3 (219.1 to 55.7) 22.9 (212.0 to 58.9)
Time of completion (imputed), s 233.1 6 86.0 267.7 6 65.8 Mean difference 34.6 (11.4 to 57.9) 32.1 (11.9 to 52.3)
TMT-B at 1 y, n 71 72
Completion in due time, n (%) 36 (50.7) 19 (26.4) Odds ratio 2.87 (1.42 to 5.78) 3.66 (1.60 to 8.35)
Without errors, n (%) 17 (47.2) 8 (42.1) Odds ratio 1.23 (0.40 to 3.78) 0.93 (0.28 to 3.09)
Time of completion (raw), s 153.4 6 71.4 132.9 6 70.3 Mean difference 220.5 (260.9 to 19.9) 218.0 (259.9 to 23.8)
Time of completion (imputed), s 225.6 6 89.5 255.9 6 82.2 Mean difference 30.2 (1.9 to 58.6) 30.3 (4.0 to 56.6)
Abbreviations: BMT 5 best medical treatment; CI 5 confidence interval; EVT 5 endovascular treatment; TMT 5 Trail Making Test.
Completion in due time refers to those who completed the test in,5 minutes. Imputed times (300 seconds) in those patients not able to complete the tests
in the requested time. Values are expressed as mean 6 SD when appropriate.
a Adjusted by age, affected hemisphere, and baseline stroke severity (NIH Stroke Scale).
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were able to complete TMT-A in due time
(5 minutes) was similar between treatment arms,
but thrombectomy increased z3-fold the odds of
timely TMT-B completion at 3 months and 1 year
after stroke (table 1). Furthermore, patients assigned to
thrombectomy required less time for test completion
and made fewer errors on TMT-A compared to those
in the medical arm (table 1).
Longer times to complete TMT were significantly
associated with larger infarct volume, higher mRS scores,
and worse quality of life (table 2).
Among those patients who reached functional inde-
pendency at 3 months (mRS score #2), all except one
completed TMT-A in the requested time in both treat-
ment arms. TMT-B was completed in due time by
z69% of patients in the thrombectomy arm and by
only 48% of patients in the best medical treatment arm
(table 3). Differences in TMT completion times in favor
of endovascular treatment were significant only in those
patients who achieved a good functional outcome (mRS
score #2) (table 3 and figure 2) and remained signifi-
cant after adjustment for aphasic symptoms and paresis
of the right upper limb (among patients with an mRS
score #2 at 3 months, only 9 had aphasic symptoms
and only one patient had right hand paresis).
DISCUSSION Our study demonstrates that in pa-
tients with acute stroke due to a proximal large vessel
occlusion, treatment with thrombectomy improves
TMT performance, a measure of cognitive function-
ing, at 3 months and 1 year after stroke. These findings
are important because they demonstrate that the
Table 2 Spearman correlation coefficients between Trail Making Test performance (completion times) and other outcome measures: Infarct
volume, functional outcome (modified Rankin Scale), and health-related quality of life (EuroQoL Group 5-Dimension Self-Report
Questionnaire 3L)
TMT-A at 3 mo (n 5 168) TMT-A at 1 y (n 5 143) TMT-B at 3 mo (n 5 168) TMT-B at 1 y (n 5 143)
Infarct volume, mL 0.24 (0.002) 0.31 (,0.001) 0.35 (,0.001) 0.29 (,0.001)
mRS score 0.56 (,0.001) 0.60 (,0.001) 0.53 (,0.001) 0.51 (,0.001)
EQ-5D (VAS) 20.25 (0.003) 20.32 (0.001) 20.25 (0.003) 20.17 (0.074)
EQ-5D (UI) 20.50 (,0.001) 20.57 (,0.001) 20.48 (,0.001) 20.47 (,0.001)
Abbreviations: EQ-5D 5 EuroQoL Group 5-Dimension Self-Report Questionnaire 3L; mRS 5 modified Rankin Scale; TMT 5 Trail Making Test; UI 5 utility
index; VAS 5 visual analog scale.
Values are expressed as Spearman correlation coefficients (r). Imputed values for completion times of TMT were used to avoid missing data in those
participants who did not complete the tests in the requested time.
Table 3 Trail Making Test performance in each treatment arm stratified by functional outcome (modified Rankin Scale score £2 and >2)
Functionally independent (mRS score £2) Functionally dependent (mRS score >2)
EVT 1 BMT BMT alone Effect SEVT 1 BMT BMT alone Effect
TMT-A at 3 mo, n 45 29 37 57
Completion in due time, n (%) 44 (98.7) 29 (100) 16 (43.2) 29 (50.9)
Time of completion, mean 6 SD, s 84.3 6 59.0 114.8 6 69.8 30.5 (0.4 to 60.6),
0.047
232.3 6 93.9 203.6 6 104.0 228.7 (270.7 to 13.3)
0.178
TMT-A at 1 y, n 39 27 32 45
Completion in due time, n (%) 39 (100) 27 (100) 15 (46.9) 21 (46.7)
Time of completion, mean 6 SD, s 70.6 6 45.5 99.5 6 62.7 28.9 (2$3 to 55$5),
0.034
215.5 6 100.2 217.3 6 101.1 1.8 (244.6 to 48.2),
0.939
TMT-B at 3 mo, n 45 29 37 57
Completion in due time, n (%) 31 (68.9) 14 (48.3) 7 (18.9) 8 (14)
Time of completion, mean 6 SD, s 193.8 6 90.6 239.5 6 81.2 45.7 (4.4 to 87.1),
0.030
280.9 6 48.5 282.1 6 51.5 1.2 (219.9 to 22.3),
0.909
TMT-B at 1 y, n 39 27 32 45
Completion in due time, n (%) 30 (76.9) 13 (48.1) 6 (18.8) 6 (13.1)
Time of completion, mean 6 SD, s 176.9 6 88.3 217.1 6 97.7 40.2 (26.0 to 86.3),
0.087
285.0 6 43.3 279.2 6 61.4 25.8 (231 to 19.3),
0.647
Abbreviations: BMT 5 best medical treatment; EVT 5 endovascular treatment; mRS 5 modified Rankin Scale; TMT 5 Trail Making Test.
Effect is expressed as mean difference between treatment arms (B coefficient and 95% confidence interval) for completion times. Time of completion
using imputed values (300 seconds) for those who were not able to complete the test in the requested time.
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benefit derived from thrombectomy, shown so far to
affect only disability and health-related quality of life,
also encompasses the cognitive domain.
Because executive dysfunction is frequently found
after stroke,1 we decided to evaluate this specific cog-
nitive domain in REVASCAT. The TMT is one of
the most commonly used neuropsychological tests. It
is easy and fast to administer and measures multiple
executive functions simultaneously: attention, pro-
cessing speed, set shifting, visuospatial ability, and
working memory.10 We found that the proportion
of patients able to complete Part A was similar
between treatment arms, although patients treated
with thrombectomy were less prone to make errors
than control patients in this specific test and required
shorter times for completion. These findings suggest
less pronounced differences in processing speed and
more substantial differences in attention and visuo-
spatial abilities between patients undergoing throm-
bectomy and patients assigned to medical treatment.
Furthermore, thrombectomy improves the comple-
tion of Part B in the requested time, a more complex
task related to cognitive flexibility.11 Regarding time
used to complete the tests, linear regression analyses
revealed significant differences in favor of thrombec-
tomy in both tests. It is important to note that in our
study, the percentage of completion of Part B in the
requested time was low, so a high proportion of
Figure 2 TMT-A (A) and TMT-B (B) completion times stratified by functional outcome (mRS score £2 and >2) in both treatment arms
Vertical axis represents completion times (seconds). Arrows and lines represent mean and 95% confidence interval of the mean. Gray arrows indicate en-
dovascular treatment (EVT); white arrows indicate best medical treatment (BMT). p Value represents unadjusted mean difference (linear regression analysis)
between treatment arms. mRS 5 modified Rankin Scale. TMT 5 Trail Making Test.
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patients received the maximum time score (300 sec-
onds). Although this is a usual practice in adminis-
tering TMT, it masks performance variability among
severely impaired patients who cannot complete the
task. Therefore, some authors have tried to find scores
that take into account not only time but also errors
and correct moves.12 Because errors and moves were
not collected in those patients who did not complete
the test in the required time, we were not able to
investigate this aspect of cognitive performance,
which should be incorporated into future trials assess-
ing the effect of reperfusion on the TMT.
In line with previous reports, we found that infarct
volume was negatively correlated with executive func-
tioning.13 Other relevant stroke outcome measures
such as health-related quality of life and disability
status were significantly and directly correlated with
poor cognitive status.
In the stratified analysis by functional independence
status, differences in TMT performance between treat-
ment arms were significant only in functionally inde-
pendent patients (mRS score #2). These findings
may therefore justify the evaluation of cognitive out-
comes in future stroke trials because they seem to pro-
vide relevant information beyond the widely used mRS.
There are several limitations to this study. First,
REVASCAT was not sized to guarantee power for sec-
ondary objectives, and the present studymay be under-
powered. Although established dementia was an
exclusion criterion for enrollment in REVASCAT
(because patients enrolled had to score 0 to 1 on the
mRS), we do not have precise information on pre-
stroke cognitive functioning of included patients;
therefore, we cannot ensure that the only factor influ-
encing TMT performance was stroke itself. Analyses
were adjusted for other covariates that may influence
understanding and ability to perform cognitive tasks
(e.g., age, stroke severity, and side of stroke). However,
data on education level, a factor known to significantly
affect cognitive function, were not collected. We do
not believe that this limitation may alter conclusions
because education level accounted only for 3% and
6% of the variance of TMT-A and TMT-B in a sample
of 911 healthy volunteers.14 In addition, symptoms of
depression/anxiety were collected only indirectly by
EQ-5D and were not included in multivariable mod-
els. Although we cannot ensure the correct balance of
prestroke cognitive status, educational level, and
depressive symptoms between treatment arms, the ran-
domized nature of the REVASCAT trial makes it at
least possible. Finally, cognitive outcome was evaluated
with only 2 cognitive tests focused on executive func-
tioning; therefore, we cannot draw conclusions on
other cognitive domains. We chose the TMT to eval-
uate cognition in REVASCAT because of its simplicity
in administration and its established correlation with
multiple cognitive dimensions. Furthermore, consensus
on optimal measurement tools for poststroke cognitive
impairment is lacking. Further studies assessing the val-
idity and reliability of different tools in the evaluation of
poststroke cognitive impairment should be performed.
Major strengths of this study include its prospective
nature, the randomized cohort of patients studied, and
the high rate of patients available for follow-up.
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CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category
1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Get Connected. Stay Connected.
Connect with the American Academy of Neurology’s popular social media channels to stay up-to-
date on the latest news and breakthroughs in neurology, and network with peers and neurology
thought leaders. Visit AAN.com/Connect.
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